Amol Akhade
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Amol Akhade
Jul 13, 2024, 18:22 |
Blog
Amol Akhade: How to treat neuroendocrine carcinoma of cervix
Amol Akhade shared on X/Twitter: "How to treat neuroendocrine carcinoma of cervix ( NECC )?…
Jul 5, 2024, 02:06 |
Insight
Amol Akhade: New combinations that are tested in MSS CRC
Amol Akhade shared on X: "What are the new combinations that are tested in MSS…
Jun 29, 2024, 14:24 |
Societies
KRAS - the most commonly mutated oncogene in cancer
Amol Akhade shared on X: "KRAS - the most commonly mutated oncogene in cancer. Nice…
Jun 27, 2024, 14:43 |
Insight
Amol Akhade: Landscape for urothelial carcinoma treatment is rapidly evolving
Amol Akhade shared on X: "The landscape for urothelial carcinoma treatment is rapidly evolving. Now…
Jun 23, 2024, 14:41 |
Blog
Amol Akhade: P53 for endometrial cancer
Amol Akhade, Consultant Medical Oncologist atSuyog Cancer Clinics, shared a post on X: "P53 for endometrial…
Jun 21, 2024, 13:14 |
Blog
Amol Akhade: What is interesting at ESMO GI24? NEST 1 trial
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X: “What…
Jun 13, 2024, 03:19 |
Drugs
Amol Akhade: Everolimus vs Alpelisib vs Capivasertib
Amol Akhade, Consultant Medical Oncologist atSuyog Cancer Clinics, shared a post on X: “Everolimus vs…
May 27, 2024, 05:50 |
Blog
Amol Akhade: A Talk about critical analysis of oncology trials in cancer Institute Adyar
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X: “Gave A…
May 5, 2024, 01:02 |
Blog
Amol Akhade: Does this ring bell for other oral drugs also?
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X: “Optimal…
Apr 24, 2024, 22:44 |
Blog
Amol Akhade: Can u pronounce name of this latest approved drug by US FDA correctly?
Amol Akhade, Consultant medical oncologist at Suyog Cancer Clinics, shared a post on X: "Can u…
Mar 8, 2024, 15:26 |
Blog
Amol Akhade: The official statement issued by Tata Memorial Hospital regarding the recent social media discussion about research done by Professor Dr. Mitra and colleagues at TMH
Mar 3, 2024, 06:41 |
Blog
Amol Akhade: How price per pill of lenalidomide kept on rising in USA
Amol Akhade, Consultant medical oncologist at Suyog Cancer Clinics, shared on X/Twitter: "How price per pill…
Feb 14, 2024, 06:32 |
Insight
Amol Akhade: What is the approach of Indian Oncologist Towards Drug approval agencies?
Amol Akhade, Consultant medical oncologist at Suyog Cancer Clinics, shared on X/Twitter: "What is the…
Feb 4, 2024, 23:52 |
Blog
Amol Akhade: So we need to make sure that low and lower middle income countries have improved access to cancer care
Amol Akhade, Consultant Medical Oncologist/Hematologist at Suyog Cancer Clinics, posted on X: “4th Feb is…
Jan 29, 2024, 17:46 |
Insight
Roberto Iacovelli: Different results from 2 phase 3 studies on adjuvant IO for mRCC... what's the reason?
Roberto Iacovelli, Associate Professor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome…
Jan 4, 2024, 16:59 |
Insight
Vinay Prasad: When do the checkpoint inhibitors work
Vinay Prasad, Professor in the Department of Epidemiology and Biostatistics at the University of California…
Dec 17, 2023, 17:26 |
Blog
25 Posts Not To Miss From SABCS 2023
The San Antonio Breast Cancer Symposium 2023 (SABCS 2023) took place in San Antonio, Texas…
Dec 12, 2023, 12:40 |
Societies
20 Posts Not To Miss From ESMO Asia Congress 2023
The ESMO Asia Congress 2023 took place in Singapore from 1 to 3 December. Our…
Nov 29, 2023, 19:32 |
Drugs
Amol Akhade: India made cervical cancer vaccine is non inferior to original made by MSD in phase 2/3 RCT
Amol Akhade, Consultant Medical Oncologist/Hematologist at Suyog Cancer Clinics, posted on Twitter: “So India made…
Nov 28, 2023, 17:12 |
Blog
Bishal Gyawali: We examine the ADAURA trial with a global oncology lens
Bishal Gyawali, Medical Oncologist and Assistant Professor at Queen's University, shared on X/Twitter: "Our new…
Oct 21, 2023, 19:37 |
Blog
Amol Akhade: Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO.
Amol Akhade, Senior Consultant in Medical and Hematooncology at the Dr Hitendra Patil's Suyog Cancer…
All:
21
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube